


Antigen-Specific Solutions for TCR-T Cell Therapy



Antigen specific interaction is at the heart of TCR-T cell therapy. In order to develop an effective T cell-based therapeutic, it is necessary to discover not only the ideal TCR, but also the most suitable target epitope.

To understand the mechanism of action of the therapeutic, the antigen-specific interaction needs to be well characterized. A thorough analysis of antigen-specific responses in T cells is critical to demonstrate efficacy and investigate possible side effects.




Quality Control of TCR-T Cell Therapies

- Demonstrate that the infusion product meets defined lot release criteria:
- T Cell Number, Identity and Purity
- Clinical-Grade [GMP] Dextramer[®] reagents
- Analyze both the identity and purity of T cells in a single step



Assess % of target-specific Dextramer[®]-positive T cells by flow cytometry

TCR-T Cell Therapy: from Development to Manufacturing



Target Discovery

TCR Discovery and Specificity Profiling

- dCODE Dextramer[®]



Infusion Product Characterization and Validation

Biochemical Characterization and Biological Applications


- Soluble TCR Monomers
- TCR Dextramer[®]
- MHC Monomers
- MHC Dextramer[®]
- dCODE Dextramer[®]



Manufacturing and Release Testing for Clinical Trials

Assessment of T Cell Number, Identity and Purity

- Clinical-Grade Dextramer[®] [GMP]



Clinical Trials


Precision Immune Monitoring of Patient Response

- TCR Dextramer[®]
- MHC Dextramer[®]
- dCODE Dextramer[®]

TCR Discovery


Perform single-cell V(D)J sequencing and TCR discovery at scale using **dCODE Dextramer®** libraries

- Multiplex up to 1000 different specificities
- Simultaneously identify the TCR sequences as well as the epitopes with which the TCRs interact
- Detect even low affinity TCRs reliably so you don't miss out on important TCR candidates



Specificity Profiling

- Perform large scale epitope recognition profiling using **dCODE Dextramer®** libraries
- Discover epitopes for which epitope-reactive TCR clonotypes with the desired phenotypic characteristics can be identified
- Investigate TCR cross-reactivity with potential off-target antigens




Assess pMHC Binding Affinity



Create plates coated with **Peptide-Receptive MHC Monomers**

- pMHC binding affinity influences the accumulation of epitope on the cell surface
- Assess the binding affinity between MHC and different target peptides

Biochemical Characterization of the TCR:pMHC Interaction




- Develop *ex vivo* assays using immobilized **Soluble TCR Monomers** and libraries of **pMHC Monomers**
- Screen for TCR Cross-Reactivity against potential off-target antigens to mitigate the risk of toxicity
- Assess TCR:pMHC binding strength using cell-free plate or bead-based binding strength and duration assays

TCR Validation

- Demonstrate TCR interaction with the target pMHC
- Assess TCR surface expression level
- Investigate TCR:pMHC complex affinity
- Characterize pMHC-reactive T cell clonotypes

MHC Dextramer® or dCODE Dextramer® bind to TCR on antigen-specific T cells enabling analysis by flow cytometry or single-cell multi-omics



T Cell Isolation, Enrichment and Expansion


Use MHC Dextramer® to

- Isolate and enrich antigen-specific T cells for further *in vitro* characterization
- Stimulate T cells so that they expand more rapidly

Precision Immune Monitoring of the Patient Response

Use MHC Dextramer® or dCODE Dextramer® in flow cytometry or single-cell multi-omics:

- Monitor kinetics and persistence of the infused T cells in patient blood samples
- Thoroughly investigate antigen-specific T-cell response to therapy
- Analyze T cell clones and their functional phenotypes
- Discover biomarkers predictive of response
- Investigate epitope spreading




APC Detection

The detection and quantification of Antigen-Presenting Cells (APCs) is important to:

- Stratify and select patients with demonstrated expression of the target antigen
- Confirm if the target antigen is present predominantly in the target tissue, and thus avoid potential toxicity
- Monitor the presence of the target antigen and possible tumor escape

TCR Dextramer® binds to pMHC on antigen-presenting cells



— Dextran ● Fluorophore Y TCR

Further Reading

Read more about how Dextramer® technology is being applied in the development of T cell-based therapeutics.

Detection and quantification of T cells:

Rapoport *et al.* Nat Med [2015] 21(8):914-921.

[doi: 10.1038/nm.3910](https://doi.org/10.1038/nm.3910)

Walseng *et al.* Sci Rep [2017] 7(1):10713.

[doi: 10.1038/s41598-017-11126-y](https://doi.org/10.1038/s41598-017-11126-y)

Proics *et al.* Gene Ther [2022]

[doi: 10.1038/s41434-022-00358-x](https://doi.org/10.1038/s41434-022-00358-x)

Foy *et al.* Nature [2022] Nov 10;1-10.

[doi: 10.1038/s41586-022-05531-1](https://doi.org/10.1038/s41586-022-05531-1)

Stevens *et al.* Authorea [2022].

[doi: 10.22541/au.165727810.00978327/v1](https://doi.org/10.22541/au.165727810.00978327/v1)

Kinetics and persistence of infused cells:

Hong *et al.* Nat Med [2023] 29, 104-114.

<https://doi.org/10.1038/s41591-022-02128-z>

Detection of APCs with TCR multimers:

Zhu *et al.* J Immunol [2006] 176(5):3223-32.

[doi: 10.4049/jimmunol.176.5.3223](https://doi.org/10.4049/jimmunol.176.5.3223)

TCR discovery:

Zhang *et al.* Sci Adv [2021] 7(20).

[doi: 10.1126/sciadv.abf5835](https://doi.org/10.1126/sciadv.abf5835)

TCR validation:

Silva *et al.* Front Immunol [2022] 13:896242.

[doi: 10.3389/fimmu.2022.896242](https://doi.org/10.3389/fimmu.2022.896242)

Vazquez-Lombardi *et al.*

Immunity [2022] 55(10):1953-1966.e10.

[doi: 10.1016/j.immuni.2022.09.004](https://doi.org/10.1016/j.immuni.2022.09.004)

Validation of specificity:

Bunse *et al.* Nat Commun 12, 240 [2021].

<https://doi.org/10.1038/s41467-020-20488-3>

Ma *et al.* Cytotherapy [2016] 18(8):985-994.

[doi: 10.1016/j.jcyt.2016.05.001](https://doi.org/10.1016/j.jcyt.2016.05.001)

Cross-reactivity screening:

Bentzen *et al.* Nat Biotechnol. [2018].

[doi: 10.1038/nbt.4303](https://doi.org/10.1038/nbt.4303)

Yamarkovich *et al.* Nature [2021] 599(7885):477-484.

[doi: 10.1038/s41586-021-04061-6](https://doi.org/10.1038/s41586-021-04061-6)

Resources

Cell Therapy

Explore how Dextramer® reagents support the development and manufacturing of effective cell therapies.

[Learn more: immudex.com/cell-therapy](https://immudex.com/cell-therapy)

TCR Discovery

Explore how TCR discovery can advance the development of novel T-cell therapies.

[Learn more: immudex.com/tcr-discovery](https://immudex.com/tcr-discovery)

Case Studies and Application Notes

Immerse yourself in educational content exploring the applications of Dextramer® technology.

[Learn more: immudex.com/education](https://immudex.com/education)

TCR Solutions

- Soluble TCR Monomers
- TCR Dextramer®

[Learn more: immudex.com/tcr-solutions](https://immudex.com/tcr-solutions)

MHC Dextramer®

- Sensitive and reliable detection of antigen-specific T cells

[Learn more: immudex.com/dextramer](https://immudex.com/dextramer)

Clinical-Grade (GMP) Dextramer®

- Extended battery of QC checks
- Established shelf-life

[Learn more: immudex.com/dextramer-gmp](https://immudex.com/dextramer-gmp)

dCODE Dextramer®

- Analysis of antigen-specific T cells by NGS or single-cell multi-omics

[Learn more: immudex.com/dCODE](https://immudex.com/dCODE)

MHC Monomers

- Ready-to-Use Monomers
- Peptide-Receptive Solutions

[Learn more: immudex.com/monomers](https://immudex.com/monomers)